The proposed iterative 4D CBCT reconstruction algorithm is more than an order of magnitude faster than other iterative algorithms described in the literature. It produces sharp, streak free images from standard 60s acquisitions used for 3D CBCT. For purposes such as patient setup and verification of tumour motion, the fast reconstruction algorithm presented enables online usage of 4D CBCT as a part of the clinical treatment routine.
Material and Methods:
Following the principles laid out in VHMR, only geometrical uncertainties are considered. We explore the use of 2D margins, motivated by the fact that small displacements in beam direction result in negligible change in dose delivered to the target. Only uncertainties perpendicular to the incident beam direction are considered, and therefore safety margins are generated for each beam direction. The degree of overlap of these beam specific margins is normalised and used to assign a weighting factor defined as the ratio of target-to-OAR content to a specific voxel. The objective function employed in the inverse planning process uses these local weighting factors for voxels of the CTV and OAR, should an overlap occur. Five prostate radiotherapy plans were generated using IMRT inverse planning. The prostate was given a prescription of 78Gy in 2Gy fractions. Systematic uncertainties of 1.1mm, 1.1mm and 1.5mm in the LR, SI and AP directions, respectively, and 2.2mm, 2.1mm, 3.2mm for the random uncertainties, were used. Plans were generated such that the static dose distribution conforms to requirements outlined in the PACE clinical trial. A verification tool was used to perform Monte Carlo simulations to model the cumulative dose of the ROI when it is displaced due to the presence of uncertainties; statistics from the tool are used for plan comparison.
Results:
We used a population of 50,000 for simulation. We observed a median of 96.7% and 100% of the population CTV receiving D98% > 95% Dpres for our approach and VHMR respectively. Both values are higher than the 90% population requirement as stated in the VHMR derivation, and this is a direct consequence of the imperfect conformality of the dose distribution. When looking at rectal doses, we observed an improvement of 20.2% to 89.2% of the population satisfying D2% < 70Gy using our method; table 1 shows the results of the simulation for the CTV, rectum and bladder for all 5 patients.
Conclusion:
We observed a significant decrease of high rectal doses delivered whilst maintaining sufficient dose coverage of the CTV, though the amount of sparing depends largely on the patient's anatomy and the objectives chosen for optimisation. Purpose or Objective: This study examines the radiationinduced changes in regional lung perfusion according to the dose level in the lungs in 58 NSCLC patients treated with chemo-radiotherapy (RT). The purpose of the study was to assess dose and time dependence of RT-induced changes in regional lung function measured with single photon emission computed tomography (SPECT) and establish a correlation with the development of radiation pneumonitis (RP).
Award Lecture: Company Award Lectures

OC-0381 Perfusion SPECT can quantify radiation-induced changes in the lung after IMRT for NSCLC K. Farr
Material and Methods:
NSCLC patients scheduled to receive RT of minimum 60 Gy were included prospectively in the study. Lung perfusion SPECT/CT was performed on a dualhead SPECT/CT camera in the treatment position before and 1, 3, 6 and 12 months after RT. Reconstructed SPECT/CT data were fused with the planning CT using MIM Software. Dose to the whole lung was segmented into regions of 0-5, 5-20, 20-40, 40-60 and >60 Gy. Regional perfusion was calculated from SPECT for each dose bin. Changes (relative to baseline, %) in regional lung perfusion were correlated with regional dose. A total of 58 patients with baseline SPECT were treated with IMRT. Of these 51 had 1 month follow-up (FU) scans, 45 had 3 months scans, 34 had 6 months scans and 23 had 12 months scans. Toxicity was assessed prospectively and graded by CTC-AE version 4 for radiation pneumonitis. Patients with minimum grade 2 were considered as RP.
Results: Composite perfusion changes were associated with dose. Statistically significant dose-dependent reduction in regional perfusion was observed at 3, 6 and 12 months FU. Comparison of dose-response curves based on their slopes showed a dose-dependent reduction in perfusion at all time intervals (R2=0.8-0.9) except 1 month (R2=0.4). Relative perfusion loss per dose bin was 4% at 1 month, 14% at 3 months, 13% at 6 months and 21% at 12 months FU (Figure 1) .
The dose-response relations varied between patients with or without RP. In patients who developed RP, perfusion reduction was larger in 20-40 Gy dose bin at 3 months FU (p=0.04), and in >60 Gy dose bin at 6 months (p=0.03), compared to those without the complication. Low dose regions, on the contrary, revealed larger perfusion increase at 12 months FU in the patients with RP (p=0.002).
Conclusion:
Progressive dose dependent perfusion loss was seen on SPECT up to 12 months following IMRT. Patients with radiation pneumonitis demonstrate a larger perfusion loss in the high dose regions, as well as relatively larger perfusion increase in regions receiving low dose, possibly due to function being shunted to these areas.
OC-0382
A novel concept to tumour targeting: inverse dose-painting or targeting the "Low uptake drug volume" A. Yaromina 1 MAASTRO clinic, Radiation Oncology, Maastricht, The Netherlands 1 , M. Granzier 1 , W. Van Elmpt 1 , R. Biemans 1 , N. Lieuwes 1 , L. Dubois 1 , P. Lambin 1 Purpose or Objective: There are several potentially radioresistant targets for dose escalation in dose-painting apporoach. Among them tumor hypoxia is a very attractive target. However, 2-3 times higher radiation dose is required to overcome hypoxia-mediated radioresistance in tumors, which is clinically difficult to achieve due to normal tissues constraints. Therefore, we propose a novel treatment approach to combine 1) targeting hypoxic tumor cells with a hypoxia-activated prodrug (HAP) TH302 and 2) at the same time use inverse radiation dose-painting strategy to boost tumor subvolumes with no/low drug uptake. We tested this approach in a rat rhabdomyosarcoma model using 18F-HX4 hypoxia tracer, which is a surrogate of TH302 accumulation in a tumor.
Material and Methods:
A clinical PET/CT scanner was used to evaluate 18F-HX4 uptake 3 hrs post injection. Low or high drug uptake volume (LDUV or HDUV) was defined as 40% of the GTV with the highest or the lowest 18F-HX4 uptake, i.e. TH302 accumulation. Within 24 hrs after PET/CT animals (n=9) received either a single dose radiotherapy (RT) uniformly or a dose-painted non-uniform irradiation with 50% higher dose to LDUV or to HDUV. Mean dose in uniform RT was 18.5 Gy similarly to the mean dose in DUV. Mean dose to the GTV in the non-uniform RT scenario was 14.9 Gy. Treatment plans were created using Eclipse treatment planning system. Animals were irradiated on a TrueBeam High Definition 120 Leaf MLC linac. Tumor response was quantified as time required to reach 3-times starting tumor volume (TGTV3).
Results: Non-uniform RT with radiation boost to tumor subvolumes with low TH302 uptake (LDUV) was much more effective than the same dose escalation to subvolumes with high drug uptake (Fig. 1) . Noteworthy, dose escalation to LDUV was as effective as uniform RT with 3.6 Gy higher mean dose to GTV. Fig. 1 .Time to reach 3-times starting tumor volume (TGTV3) after uniform RT or non-uniform RT with dose escalation to tumor volume with high drug uptake (HDUV) or low drug uptake (LDUV). Mean dose (Dm) to GTV is indicated.
Conclusion:
The results of this pilot study support targeted dose escalation in non-hypoxic tumor subvolumes with no/low accumulation of hypoxia-activated prodrugs, which requires further confirmation. This strategy appears to be as effective as a uniform dose escalation of the entire GTV but with greater capacity to spare normal tissues. It is expected that this approach of inverse dose-painting can be combined with other imageable cytotoxic drugs, which warrants further investigations. The implicit concept behind the title of this lecture concerns the role of "quantitative" data-driven approaches in assessing dose-volume effects in normal tissues in the era of "high-tech" radiotherapy and integration of "omics". The continuously growing literature regarding dose-volume relationships indirectly reflects the need of improving and refining our knowledge in this field [1] . This seems to be particularly urgent in a number of clinically relevant situations such as, for instance, heart, bowel and bladder. However, the impact of the above mentioned elements ("high-tech & "omics") on the research issues of this field is increasingly relevant and claims for the development of new research lines and methods that will shortly be overviewed in the lecture.
